Compare PRDO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRDO | BEAM |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | N/A | 2020 |
| Metric | PRDO | BEAM |
|---|---|---|
| Price | $28.18 | $26.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $42.00 | ★ $48.09 |
| AVG Volume (30 Days) | 841.9K | ★ 2.1M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 17.26 | N/A |
| EPS | ★ 2.33 | N/A |
| Revenue | ★ $810,888,000.00 | $55,701,000.00 |
| Revenue This Year | $26.43 | N/A |
| Revenue Next Year | $3.65 | $26.52 |
| P/E Ratio | $12.11 | ★ N/A |
| Revenue Growth | ★ 24.23 | N/A |
| 52 Week Low | $23.87 | $13.53 |
| 52 Week High | $38.03 | $35.25 |
| Indicator | PRDO | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 57.99 |
| Support Level | $27.56 | $23.30 |
| Resistance Level | $28.59 | $29.16 |
| Average True Range (ATR) | 0.90 | 1.71 |
| MACD | 0.17 | 0.52 |
| Stochastic Oscillator | 45.21 | 73.17 |
Perdoceo Education Corp is an American for-profit education company that focuses on quality postsecondary education online to a diverse student population, along with campus-based and blended learning programs. The company's important segments include the American InterContinental University, the University of St. Augustine for Health Sciences, and Colorado Technical University. These universities provide undergraduate, graduate, and doctoral degree programs focusing on business, technology, management, and social services, with the majority of the students enrolled in programs offered fully online. The majority of the company's revenue comes from the Colorado Technical University segment.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.